Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Immunogenicity of Influenza H9 Vaccine in Humans
This study has been completed.
Study NCT00814229   Information provided by University Hospitals, Leicester

First Received on December 23, 2008.   Last Updated on July 20, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Influenza
Additional conditions recognized in this trial
Influenza, Human
More general conditions related to this trial
Orthomyxoviridae Infections
Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
H9N2 whole virus, alum, IM, 5microg
H9N2 virosomal vaccine, IM, 5microg
Additional drug interventions recognized in this trial
Aluminum sulfate
Hemagglutinins
N-(2-aminoethyl)-5-isoquinolinesulfonamide
More general drug interventions related to this trial
Adjuvants, Immunologic
Agglutinins
Enzyme Inhibitors
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Sponsors listed in this trial
University Hospitals, Leicester
Crucell Holland BV
National Institute of Biological Standards and Control
Health Protection Agency, United Kingdom


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services